Nanexa AB (publ) (NANEXA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to this report interview and final communication interview with the drug delivery company Nanexa in the fourth quarter. With us from the company is CEO Göran Ando and CEO David Westberg. Today we will start with a presentation of Göran Ando's GLP-1 overview before we let David in to comment on the quarter and they are both here in the studio. You who are watching can ask questions via live chat. Ladies and gentlemen, welcome. Thank you. It's great to have you here again. David, how happy are you with the report? I am very happy. I am very happy with the conclusion of last year when we got the study results from our NEXU 2 project. Very happy. And Göran, you will give us an insight into the wonderful world of GLP-1s. I will try to give a short glimpse of what has happened during the last few months. This is an area that moves quite quickly, as you probably know. And not everyone follows it so closely. What I say is of course my opinions and my interpretation of it all. That's how I have to talk about it. There are only two companies that have approved preparations in the area. It is Nordic and it is Eli Lilly. In principle, they both have two preparations each. They ended the year in 2024 with sales between 20 and 30 billion dollars. So this is a very similar class together. They share roughly on the market right now in the USA, where you have the freshest data. In the rest of the world, Nordic is larger, but the big economic incitement right now is in the USA. What has happened? Nordic presented, just before Christmas, phase 3 results from its new, which is a solid combination preparation between semaglutide, i.e. Osempic, Vegui, and an amylin product called Kagri 99. The product is called Kagri Sema, at least right now. and they predicted a weight loss of 23...